Guerbet — Board/Management Information 2011

May 30, 2011

P R E S S R E L E AS E

Death of Bernard Massiot, Guerbet CEO

Villepinte, 30 May 2011

Bernard Massiot, CEO of the Guerbet group, passed away on 28 May 2011, at the age of fifty-five following a battle with cancer.

Every one of Guerbet's 1,300 staff felt great sadness at the announcement of his death.

He became a director of the company in 1993, then vice-chairman of the supervisory board, becoming its CEO in January 2010.

In the words of Jean-Jacques Bertrand, Chairman of the Board of Directors, "Bernard Massiot, one of Dr. Michel Guerbet's nephews, was a very dynamic director, very rigorous and clear-think thinking with great human qualities. Over the last year and a half he has given a fresh impetus to the Group and initiated a great number of transformations".

Bernard Massiot was a graduate of Paris-Dauphine University and had a degree in Public Accounting. He began his career in audit and finance and subsequently took on responsibilities in general management in companies in the press and media industries, in industry (in north-east France) and services, primarily in France and in Europe.

The Board of Directors, its chairman and the management team will ensure the continuity of the work undertaken by Bernard Massiot. They will make it their duty to respect the spirit of his work, thus enabling Guerbet to achieve its ambition of being a major player in medical imaging.

About Guerbet

Guerbet is the only pharmaceutical group totally dedicated to medical imaging on the world market. It has a comprehensive range of X-ray, MRI and nuclear medicine imaging products to enhance overall patient care. Its products facilitate diagnosis and the preparation of treatment strategies for major pathologies (cardiovascular diseases, cancers, inflammatory and degenerative diseases).

To discover new products and ensure its future development, Guerbet devotes significant resources to R&D every year: 210 staff and a sum equivalent to 11% of its sales. The programs on MRI and nuclear medicine modalities are central to Guerbet's research priorities.

Guerbet has a very strong presence in Europe with a market share of 25% and is developing its presence in the United States, South America and Asia.

Guerbet, listed on the Euronext Paris Eurolist (compartment B), posted sales of €352 million in 2010 with a total headcount of 1300.

For more information about Guerbet, please go to www.guerbet.com.

Press contacts: Anne-Laure Delasalle, VP Communications & Image

Tel: 01 45 91 50 03

anne-laure.delasalle@guerbet-group.com